CD8A and neoplasm: SCD1 was found that expressed in cancer cells and immune cells causes immune-resistant conditions, inhibition of SCD1 enhances the recruitment of dendritic cells into tumors and the subsequent induction and tumor accumulation of antitumor CD8+ T cells, thus this gene was identified as a potential target to enhance the antitumor effects of an anti-PD-1 therapy54.